Pharmacological Targeting of AMP-Activated Protein Kinase and Opportunities for Computer-Aided Drug Design: Miniperspective
The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
As a central regulator of metabolism, the AMP-activated protein kinase (AMPK) is an established therapeutic target for metabolic diseases. Beyond the metabolic area, the number of medical fields that involve AMPK grows continuously, expanding the potential applications for AMPK modulators. Even though indirect AMPK activators are used in the clinics for their beneficial metabolic outcome, the few described direct agonists all failed to reach the market to date, which leaves options open for novel targeting methods. As AMPK is not actually a single molecule and has different roles depending on its isoform composition, the opportunity for isoform-specific targeting has notably come forward, but the currently available modulators fall short of expectations. In this review, we argue that with the amount of available structural and ligand data, computer-based drug design offers a number of opportunities to undertake novel and isoform-specific targeting of AMPK.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“irreversible AMPK blockade in hypoxic-ischemic brain damage was shown to exacerbate neuronal death [59].”
From AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma (2021) · cites this paper as [59]
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
AMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Mechanisms for Insulin Resistance: Common Threads and Missing Links
Samuel, V. T., & Shulman, G. I. (2012) · Cell · doi:10.1016/j.cell.2012.02.017 · Cited by 2,294
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943
Cool, B., Zinker, B., Chiou, W., Kifle, L., Cao, N., Perham, M., Dickinson, R., Adler, A., Gagne, G., Iyengar, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.005 · Cited by 925
Cantó, C., Jiang, L. Q., Deshmukh, A. S., Mataki, C., Coste, A., Lagouge, M., Zierath, J. R., & Auwerx, J. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.02.006 · Cited by 921
The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase
Hawley, S. A., Fullerton, M. D., Ross, F. A., Schertzer, J. D., Chevtzoff, C., Walker, K. J., Peggie, M. W., Zibrova, D., Green, K. A., Mustard, K. J., et al. (2012) · Science · doi:10.1126/science.1215327 · Cited by 739
Characterization of AMP-activated protein kinase γ-subunit isoforms and their role in AMP binding
CHEUNG, P. C. F., SALT, I. P., DAVIES, S. P., HARDIE, D. G., & CARLING, D. (2000) · Biochemical Journal · doi:10.1042/bj3460659 · Cited by 637
Cited by
Adenosine Monophosphate (AMP)-Activated Protein Kinase: A New Target for Nutraceutical Compounds
Marín-Aguilar, F., Pavillard, L., Giampieri, F., Bullón, P., & Cordero, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020288 · Cited by 98
Promise and challenges for direct small molecule AMPK activators
Olivier, S., Foretz, M., & Viollet, B. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.049 · Cited by 85
Belforte, N., Agostinone, J., Alarcon-Martinez, L., Villafranca-Baughman, D., Dotigny, F., Cueva Vargas, J. L., & Di Polo, A. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00466-z · Cited by 67
“For example, irreversible AMPK blockade in hypoxic-ischemic brain damage was shown to exacerbate neuronal death [59].”
BackgroundCameron, K. O., & Kurumbail, R. G. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.09.065 · Cited by 45
Targeting AMPK: From Ancient Drugs to New Small-Molecule Activators
Guigas, B., & Viollet, B. (2016) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-319-43589-3_13 · Cited by 46
Coccimiglio, I. F., & Clarke, D. C. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008079 · Cited by 34
Nayarisseri, A. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/156802662019200701164759 · Cited by 34
Bort, A., Quesada, S., Ramos‐Torres, Á., Gargantilla, M., Priego, E., Raynal, S., Lepifre, F., Gasalla-Herraiz, J., Rodríguez‐Henche, N., Castro, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22690-2 · Cited by 26
Huang, T., Sun, J., Zhou, S., Gao, J., & Liu, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071408 · Cited by 23
“The γ subunit is composed of a β subunit-binding region and two Bateman domains [11].”
BackgroundTargeting of AMP-activated protein kinase: prospects for computer-aided drug design
Kim, J., Yang, G., & Ha, J. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1255194 · Cited by 23
“Accumulating reports have tried to identify novel AMPK modulators in the basis of virtual screenings and the subsequent computer-aided drug design [85,86].”
BackgroundKumar, R., Maurya, R., & Saran, S. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1441069 · Cited by 17
Žuvela, P., Liu, J. J., Yi, M., Pomastowski, P., Sagandykova, G. N., Belka, M., David, J., Bączek, T., Szafrański, K., Żołnowska, B., et al. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1511551 · Cited by 17
“Although not as popular in drug discovery as protein kinases, 23 – 26 cancer-associated CA IX is still an interesting target due to its correlation with tumor cells proliferation 27 – 29 In fact, a sulphonamide derivative selective to CA IX and CA XII developed in 2011 (SLC-0111) has recently…”
BackgroundVascular adenosine monophosphate‐activated protein kinase: Enhancer, brake or both?
Chen, H., Vanhoutte, P. M., & Leung, S. W. S. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13357 · Cited by 15
Chen, H., Vanhoutte, P. M., & Leung, S. W. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14716 · Cited by 13
“A769662 and AICAR bind to different sites of AMPK (the former is a β1‐selective activator, while the active metabolite of the latter binds to the γ‐subunit, resulting in exposure of the kinase domain in the α‐subunit; Miglianico et al., 2015; Salt & Hardie, 2017); however, the absence of a different distribution of en…”
BackgroundThe Role of AMP-activated Protein Kinase in Oxytosis/Ferroptosis: Protector or Potentiator?
Currais, A. J. M., Kepchia, D., Liang, Z., & Maher, P. A. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0013 · Cited by 13
“In theory, AMPK can be indirectly activated by any compound that causes AMP or calcium accumulation (for reviews see 43, 48, 51, 57, 77, 88).”
InfluentialRozentul, N., Avrahami, Y., Shubely, M., Levy, L., Munder, A., Cohen, G., Cerasi, E., Sasson, S., & Gruzman, A. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2271-7 · Cited by 10
In silico screening of a novel scaffold for fructose-1,6-bisphosatase (FBPase) inhibitors
Huang, Y., Chi, B., Xu, Y., Song, R., Wei, L., Rao, L., Feng, L., Ren, Y., & Wan, J. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.10.017 · Cited by 10
Li, H., Hua, W., Wang, Z., Liu, A., Jiang, J., & Luo, Y. (2020) · The Journal of Physical Chemistry A · doi:10.1021/acs.jpca.9b10756 · Cited by 8
Allosteric Modulation of AMPK Enzymatic Activity
Ward, J., Reyes, A. R., & Kurumbail, R. G. (2016) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2016.10.010 · Cited by 4
Biophysical Interactions of Direct AMPK Activators
Kurumbail, R. G., West, G. M., Dharmarajan, V., Borzilleri, K. A., Withka, J. M., Ward, J., Reyes, A. R., Rajamohan, F., Griffin, P. R., & Calabrese, M. F. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7598-3_3 · Cited by 4
Kitisripanya, T., Buraphaka, H., Boonsnongcheep, P., Sritularak, B., Likhitwitayawuid, K., & Putalun, W. (2021) · ScienceAsia · doi:10.2306/scienceasia1513-1874.2021.107 · Cited by 2
“In recent years, AMPK activators, based on theirs reported actions in the liver and the skeletal muscle, have been known as a promising pharmacological target for the prevention and the treatment of type 2 DM and metabolic diseases [2, 3].”
BackgroundPatil, R. B., Owoseeni, O. D., Phage, P. M., Famuyiwa, S. O., Gboyero, F. O., Arowojolu, G. M., & Faloye, K. O. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230417124235
Belforte, N., Agostinone, J., Alarcón-Martínez, L., Villafranca‐Baughman, D., Dotigny, F., Vargas, J. C., & Polo, A. D. (2021) · Figshare · doi:10.6084/m9.figshare.14880590
Belforte, N., Agostinone, J., Alarcón-Martínez, L., Villafranca‐Baughman, D., Dotigny, F., Vargas, J. C., & Polo, A. D. (2021) · Figshare · doi:10.6084/m9.figshare.14880593
Metadata
- Authors
- Miglianico, M., Nicolaes, G. A. F., & Neumann, D.
- Affiliations
- Maastricht University (NL)
- Corresponding author
- Miglianico, Marie
- Neumann, Dietbert
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-11-09
- Volume
- 59
- Issue
- 7
- Pages
- 2879-2893
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2340359231
- Cited by
- 24
- References
- 89
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 2 · 2018: 6 · 2017: 3 · 2016: 4
- FWCI
- 0.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (864.10.007, 91112016)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- AMPK, AMPK agonists, AMPK isoforms, computer-aided drug design, metabolic disorders, kinase inhibitors, structure-based drug design
- MeSH terms
- Animals, Brain, Enzyme Activation, Humans, Insulin Resistance, Ligands, Neoplasms, Structure-Activity Relationship, Drug Design, Signal Transduction, Computer-Aided Design, Protein Kinase Inhibitors, AMP-Activated Protein Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.